Vonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Nonerosive Reflux Disease
Open Access
- 13 October 2025
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (8) , 1866-1874
Abstract
INTRODUCTION: This analysis of a phase 3 randomized trial evaluated the efficacy of vonoprazan on prespecified end points for nighttime symptoms in patients with nonerosive reflux disease. METHODS: Adults with heartburn ≥4 d/wk and without erosive esophagitis were randomized to placebo, vonoprazan 10 mg, or vonoprazan 20 mg. After 4 weeks, subjects on placebo were rerandomized to vonoprazan 10 or 20 mg, and those already on vonoprazan continued the same dose for an additional 20 weeks. Nocturnal Gastro-esophageal Reflux Disease Symptom Severity and Impact Questionnaire (N-GSSIQ), a validated instrument for nocturnal gastroesophageal reflux disease, was completed at baseline and weeks 4, 12, and 24. Minimal important differences for N-GSSIQ total score and subscales were defined as ≥0.4. RESULTS: Among 772 subjects, the mean percentage of heartburn-free nights at week 4 was 43.3% for placebo vs 59.9% for vonoprazan 10 mg (least squares [LS] mean difference = 16.5%, P < 0.0001) and 56.4% for vonoprazan 20 mg (LS mean difference, 13.1%, P < 0.0001). Vonoprazan improved N-GSSIQ total score (LS mean difference vs placebo of −2.9 and −1.8 for vonoprazan 10 and 20 mg, respectively; P < 0.005 for both comparisons), nocturnal symptom severity subscale (LS mean difference vs placebo of −5.4 and −3.5 for vonoprazan 10 and 20 mg; P < 0.001 for both comparisons), and concern about nocturnal gastroesophageal reflux disease subscale (LS mean difference vs placebo of −2.0 for both vonoprazan 10 and 20 mg; P < 0.0001). The benefit on heartburn-free nights and N-GSSIQ scores was observed through the additional 20 weeks. DISCUSSION: Our study suggests that vonoprazan leads to relief of nighttime heartburn in patients with heartburn and a normal endoscopy.Keywords
Funding Information
- Phathom Pharmaceuticals
This publication has 25 references indexed in Scilit:
- Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized TrialClinical Gastroenterology and Hepatology, 2024
- Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized TrialGastroenterology, 2022
- AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert ReviewClinical Gastroenterology and Hepatology, 2022
- Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory SymptomsGastroenterology, 2020
- Questionnaire based gastroesophageal reflux disease (GERD) assessment scalesIndian Journal of Gastroenterology, 2011
- The Effect of Dexlansoprazole MR on Nocturnal Heartburn and GERD-Related Sleep Disturbances in Patients With Symptomatic GERDAmerican Journal of Gastroenterology, 2011
- Rabeprazole 20 mg for Erosive Esophagitis-Associated Symptoms in a Large, Community-Based Study: Additional ResultsDigestive Diseases and Sciences, 2009
- Comparison of morning and evening administration of rabeprazole for gastro‐oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double‐blind, cross‐over studyAlimentary Pharmacology & Therapeutics, 2003
- Symptoms Associated with Gastroesophageal Reflux DiseaseDigestive Diseases and Sciences, 2001
- The Impact of Nocturnal Symptoms Associated With Gastroesophageal Reflux Disease on Health-Related Quality of LifeArchives of internal medicine (1960), 2001